CA1087631A - 2-phenylpropionic acid derivative and process for its preparation - Google Patents
2-phenylpropionic acid derivative and process for its preparationInfo
- Publication number
- CA1087631A CA1087631A CA295,499A CA295499A CA1087631A CA 1087631 A CA1087631 A CA 1087631A CA 295499 A CA295499 A CA 295499A CA 1087631 A CA1087631 A CA 1087631A
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- acid
- bromine
- iodine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title claims description 9
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 title abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims abstract description 9
- 230000020477 pH reduction Effects 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- 238000007127 saponification reaction Methods 0.000 claims abstract description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 82
- 239000000460 chlorine Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 20
- 229910052794 bromium Inorganic materials 0.000 claims description 20
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Chemical group 0.000 claims description 16
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 9
- 125000001246 bromo group Chemical group Br* 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 9
- 239000001117 sulphuric acid Substances 0.000 claims description 9
- 235000011149 sulphuric acid Nutrition 0.000 claims description 9
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 7
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 claims description 5
- 150000004703 alkoxides Chemical class 0.000 claims description 4
- 238000006114 decarboxylation reaction Methods 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 230000011987 methylation Effects 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910006069 SO3H Inorganic materials 0.000 claims description 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011630 iodine Chemical group 0.000 claims description 2
- 229910052740 iodine Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 73
- 230000001035 methylating effect Effects 0.000 claims 3
- 239000000543 intermediate Substances 0.000 claims 2
- KYHPZLOCYZGUFF-UHFFFAOYSA-N 2-[(3-chloro-4-methoxyphenyl)methyl]propanedioic acid Chemical compound COC1=CC=C(CC(C(O)=O)C(O)=O)C=C1Cl KYHPZLOCYZGUFF-UHFFFAOYSA-N 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 230000000911 decarboxylating effect Effects 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 21
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000010992 reflux Methods 0.000 description 11
- 235000019260 propionic acid Nutrition 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 6
- 229960005142 alclofenac Drugs 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- -1 Aliphatic halogenated hydrocarbons Chemical class 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101100112336 Homo sapiens CASP5 gene Proteins 0.000 description 1
- 101100273286 Mus musculus Casp4 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000000307 algesic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE:
A new derivative of 2-phenylpropionic acid of the formula (I) is obtained by subjecting a corresponding alkyl ester of the formula:
A new derivative of 2-phenylpropionic acid of the formula (I) is obtained by subjecting a corresponding alkyl ester of the formula:
Description
~08~63~
The present inVention iS concerned with a new derivative of 2-phenylpropionic acid of the formula:
~ CH - O - ~ 1 3 (I) and its pharmaceutically acceptable addition salts.
The present invention also provides a process for the preparation of the above derivative according to Scheme A
Scheme A
Cl Cl CH30- ~ -CH2-CN -- 1 / 4 2 ~ CH30 ~ CH2-COOR
II O IC / 2H5 ~ III
OR
Cl COORl ~CH3/C2H5ONa Cl COOR~.
CH30- ~ -CH l)OH ~ CH30- ~ C00R2 Cl ~ 2)H+ C
CH ~ ~ IC 3 XH~or -~ HO ~ -CH-COOH
3 BrH!S04H2 ~ ~
VI Rl-OH/Ar-SO3H / VII
Cl / Cl ~ CH3 L ~ D -CH2-X ~ CH -~ ~ O~ -CH-COOR
HO- ~ -CH-COORl ~ 2 VIII / IX
1)~ ' . . .
~ CH2-0- ~ C 3 H+
. . ,- . .: , -- , . .
1~87631 The present invention also provides two variations of the process according to the above scheme A, comprising further synthesis steps for the preparation of the intermediate compound of the formula VII. From VII, the preparation of compound I
is carried out according to scheme A given above. The new processes are thoroughly described in schemmes B and C :
Scheme B C ~
Cl ~ YCH3 CH 0- ~ -CH-CN
CH30~ CH2-CN _ ~ 3 \___/ OHNa/S04H . ~(C4Hg)4 II
XH
Cl~ ~ ICH3 ~~/rH/s04H2 . ~ ' . ' HO- < ~ -CH- OOH
VII
Scheme C
Cl Cl ~ YCH3 ~ CIH3 CH30- ~ CH2 C00RlNH2Na , NH3(liq.) ~ -CH-COOR
III ~ XI
XH
~~
Cl A ICH
HO- ~ O ~ -CH-COOH
VII
According to scheme A, /3-chloro-4-methoxypheny~
acetonitrile (II) is treated, under cold conditions, with an alkanol of formula Rl-OH where Rl is a lower alkyl radical, in a strong acid, preferably sulphuric acid to give an alkyl ~3-chloro-4-methoxypheny ~ acetate tIII)~ for example, ethylic.
Compound (III) is treated with a carbonic acid derivative of formula (R2O)2CO, where R2 is an alkyl radical of low molecular weight which may be equal or not to Rl, such as diethyl carbonate,
The present inVention iS concerned with a new derivative of 2-phenylpropionic acid of the formula:
~ CH - O - ~ 1 3 (I) and its pharmaceutically acceptable addition salts.
The present invention also provides a process for the preparation of the above derivative according to Scheme A
Scheme A
Cl Cl CH30- ~ -CH2-CN -- 1 / 4 2 ~ CH30 ~ CH2-COOR
II O IC / 2H5 ~ III
OR
Cl COORl ~CH3/C2H5ONa Cl COOR~.
CH30- ~ -CH l)OH ~ CH30- ~ C00R2 Cl ~ 2)H+ C
CH ~ ~ IC 3 XH~or -~ HO ~ -CH-COOH
3 BrH!S04H2 ~ ~
VI Rl-OH/Ar-SO3H / VII
Cl / Cl ~ CH3 L ~ D -CH2-X ~ CH -~ ~ O~ -CH-COOR
HO- ~ -CH-COORl ~ 2 VIII / IX
1)~ ' . . .
~ CH2-0- ~ C 3 H+
. . ,- . .: , -- , . .
1~87631 The present invention also provides two variations of the process according to the above scheme A, comprising further synthesis steps for the preparation of the intermediate compound of the formula VII. From VII, the preparation of compound I
is carried out according to scheme A given above. The new processes are thoroughly described in schemmes B and C :
Scheme B C ~
Cl ~ YCH3 CH 0- ~ -CH-CN
CH30~ CH2-CN _ ~ 3 \___/ OHNa/S04H . ~(C4Hg)4 II
XH
Cl~ ~ ICH3 ~~/rH/s04H2 . ~ ' . ' HO- < ~ -CH- OOH
VII
Scheme C
Cl Cl ~ YCH3 ~ CIH3 CH30- ~ CH2 C00RlNH2Na , NH3(liq.) ~ -CH-COOR
III ~ XI
XH
~~
Cl A ICH
HO- ~ O ~ -CH-COOH
VII
According to scheme A, /3-chloro-4-methoxypheny~
acetonitrile (II) is treated, under cold conditions, with an alkanol of formula Rl-OH where Rl is a lower alkyl radical, in a strong acid, preferably sulphuric acid to give an alkyl ~3-chloro-4-methoxypheny ~ acetate tIII)~ for example, ethylic.
Compound (III) is treated with a carbonic acid derivative of formula (R2O)2CO, where R2 is an alkyl radical of low molecular weight which may be equal or not to Rl, such as diethyl carbonate,
- 2 -~ .
..,~._:. i .. '' 108763~
in a basic medium such as that constituted by an alkaline alkoxide in an alkanol of low molecular weight, to give a dialkyl /3-chloro-4-methoxypheny~/malonate (IV). Compound (IV) is methylated with a compound of formula YCH3 where Y is bromine or iodine, preferably iodine, in the presence of an alkaline alkoxide in an alkanol of low molecular weight to - give dialkyl /3-chloro-4-methoxypheny~/ methylmalonate (V).
In the preparation of compounds (IV) and (V), sodium ethoxide in ethanol is commonly used as a basic medium which is suitable for malonation and methylation. Compound (V), by basic -:
hydrolysis preferably under reflux in the presence of sodium hydroxide in ethanol (it is also possible to use other alkaline or earth-alkaline hydroxides dissolved in an alkanol of low molecular weight), subsequent acidification and decarboxylation provides a-/3-chloro-4-methoxypheny~/ propionic acid (VI).
There may be used a mineral acid, such as hydrochloric acid, for the acidification. The decarboxylation is generally carried out by heating the intermediate /3-chloro-4-methoxypheny~/
methyl malonic acid, in form of crude product, at 210-220C. :
Compound (VI) is demethylated by acid hydrolysis with an hydracide of formula XH, where X is chlorine, bromine or iodine, preferably bromine, or a mixture of sulphuric acid with bromhydric acid, the latter being a desirable reactant only when it is required to extremely accelerate the process since bromhydric acid is the only acid catalyst suitable for the reaction. The a-/3-chloro-4-hydroxypheny~J propionic acid :~
(VII) which is obtained is then treated under reflux with a low molecular-weight alkanol such as methanol, by using an aryl-sulphonic acid, as a catalyst, of formula Ar-S03H where :
Ar is a phenyl radical, which may contain one or more lower alkyl radicals to give alkyl a-~3-chloro-4-hydroxypheny ~
propionate (VIII). Compound (VIII) is treated in a basic : , - - , :: ,, , :
medium such as an alkaline or earth-alkaline carbonate in a low molecular-weight ketone, preferably acetone, with a ~-halomethyl-cyclopropane of formule P-CH2-X where X is chlorine, bromine or iodine. Thus, alkyl ~-/3-chloro-4-cyclopropylmethoxyJ-propionate (IX) is obtained which, on saponification with an alkaline or earth-alkaline hydroxide dissolved in a low molecular-weight alkanol and subsequent acidification with a mineral acid, such as hydrochloric acid, leads to the desired compound (I). Potassium hydroxide in methanol is suitably used as an alkaline hydroxide in a low molecular-weight alkanol.
Schemes B and C show two synthesis options for the preparation of the intermediate (VII) thus shortening the -number of reactions steps. Through Scheme 2, compound (II) is methylated with a compound of formula YCH3 where Y is bromine or iodine, preferably methyl iodide, in the presence of an alkaline or earth-alkaline hydroxide and an ammonium salt, sodium hydroxide and tetrabutylammonium acid sulphate being suitably used. Aliphatic halogenated hydrocarbons such as methylene chloride is commonly used as a suitable solvent for this reaction. The a-/3-chloro-4-methoxypheny~/ propioni-trile ~X) which is obtained is then hydrolized in an acid solu-tion according to the same procedure as that used in the hydrolisis of compound (VI), thus obtaining the intermediate (VII) from which the preparation of compound (I) is accomplished as in Scheme A.
In Scheme C, compound (III) is methylated with a reactant of the formula YCH3 where Y is bromine or iodine, preferably methyl iodide, in the presence of a strong base such as sodamide in liquid ammonia. Thus, ethyl ~-/3-chloro-4-methoxyphenylJ propionate (XI) is obtained. The acid hydro-lysis, preferably with bromhydric acid, leads to the intermediate ~ . . : . .
~87631 (VII), from which the preparation of compound (I) is accomplish-ed as in the scheme A given above.
The compound (I) once obtained may be transformed into its pharmaceutically acceptable addition salts according to the usual chemical methods.
The new compound, a-/3-chloro-4-cyclopropylmethyloxi-pheny ~ propionic acid (I) shows anti-inflammatory, analgesic and antipiretic properties.
The anti-inflammatory activity has been determined for compound (I) by comparison with Alclofenac, as per the Carrageenan test comprising the oral administration of the test compound suspended in oil to albino female rats with 100 g average weight one hour before the subcutaneous perfusion of 0.1 ml of 1% carrageenan in distilled water into the hind-right paw of the rat.
In Table l,the activity is expressed as the decrease rate of the induced edema volume and is hereinafter computed for a series of dosage.
_ Compound I Alclofenac _ Dose (mg/kg) Activity (%) Dose (mg/kg) Activity (%) .:
2.5 25.7 2.5 16.88 35.45 5 23.38 45.79 10 28.52 .
The antipiretic activity has been determined for compound (I) by comparison with Alclofenac. The method used consisted in inducing fever in albino male rats (100-150 g weight) by subcutaneous injection of brewer's yeast (20%
suspension in sodium chloride 0.9 % dissolution) at a dose of 10 ml/kg.
~
: - . . . .
.: , : . :. : . :~
108~7631 In Table 2, the activity is expressed as the decrease rate of the induced temperature and is hereinafter computed for a series of dosage.
Compound I Alclofenac Dose (mg/kg) Activity (%)Dose (mg/kg) Activity (%)
..,~._:. i .. '' 108763~
in a basic medium such as that constituted by an alkaline alkoxide in an alkanol of low molecular weight, to give a dialkyl /3-chloro-4-methoxypheny~/malonate (IV). Compound (IV) is methylated with a compound of formula YCH3 where Y is bromine or iodine, preferably iodine, in the presence of an alkaline alkoxide in an alkanol of low molecular weight to - give dialkyl /3-chloro-4-methoxypheny~/ methylmalonate (V).
In the preparation of compounds (IV) and (V), sodium ethoxide in ethanol is commonly used as a basic medium which is suitable for malonation and methylation. Compound (V), by basic -:
hydrolysis preferably under reflux in the presence of sodium hydroxide in ethanol (it is also possible to use other alkaline or earth-alkaline hydroxides dissolved in an alkanol of low molecular weight), subsequent acidification and decarboxylation provides a-/3-chloro-4-methoxypheny~/ propionic acid (VI).
There may be used a mineral acid, such as hydrochloric acid, for the acidification. The decarboxylation is generally carried out by heating the intermediate /3-chloro-4-methoxypheny~/
methyl malonic acid, in form of crude product, at 210-220C. :
Compound (VI) is demethylated by acid hydrolysis with an hydracide of formula XH, where X is chlorine, bromine or iodine, preferably bromine, or a mixture of sulphuric acid with bromhydric acid, the latter being a desirable reactant only when it is required to extremely accelerate the process since bromhydric acid is the only acid catalyst suitable for the reaction. The a-/3-chloro-4-hydroxypheny~J propionic acid :~
(VII) which is obtained is then treated under reflux with a low molecular-weight alkanol such as methanol, by using an aryl-sulphonic acid, as a catalyst, of formula Ar-S03H where :
Ar is a phenyl radical, which may contain one or more lower alkyl radicals to give alkyl a-~3-chloro-4-hydroxypheny ~
propionate (VIII). Compound (VIII) is treated in a basic : , - - , :: ,, , :
medium such as an alkaline or earth-alkaline carbonate in a low molecular-weight ketone, preferably acetone, with a ~-halomethyl-cyclopropane of formule P-CH2-X where X is chlorine, bromine or iodine. Thus, alkyl ~-/3-chloro-4-cyclopropylmethoxyJ-propionate (IX) is obtained which, on saponification with an alkaline or earth-alkaline hydroxide dissolved in a low molecular-weight alkanol and subsequent acidification with a mineral acid, such as hydrochloric acid, leads to the desired compound (I). Potassium hydroxide in methanol is suitably used as an alkaline hydroxide in a low molecular-weight alkanol.
Schemes B and C show two synthesis options for the preparation of the intermediate (VII) thus shortening the -number of reactions steps. Through Scheme 2, compound (II) is methylated with a compound of formula YCH3 where Y is bromine or iodine, preferably methyl iodide, in the presence of an alkaline or earth-alkaline hydroxide and an ammonium salt, sodium hydroxide and tetrabutylammonium acid sulphate being suitably used. Aliphatic halogenated hydrocarbons such as methylene chloride is commonly used as a suitable solvent for this reaction. The a-/3-chloro-4-methoxypheny~/ propioni-trile ~X) which is obtained is then hydrolized in an acid solu-tion according to the same procedure as that used in the hydrolisis of compound (VI), thus obtaining the intermediate (VII) from which the preparation of compound (I) is accomplished as in Scheme A.
In Scheme C, compound (III) is methylated with a reactant of the formula YCH3 where Y is bromine or iodine, preferably methyl iodide, in the presence of a strong base such as sodamide in liquid ammonia. Thus, ethyl ~-/3-chloro-4-methoxyphenylJ propionate (XI) is obtained. The acid hydro-lysis, preferably with bromhydric acid, leads to the intermediate ~ . . : . .
~87631 (VII), from which the preparation of compound (I) is accomplish-ed as in the scheme A given above.
The compound (I) once obtained may be transformed into its pharmaceutically acceptable addition salts according to the usual chemical methods.
The new compound, a-/3-chloro-4-cyclopropylmethyloxi-pheny ~ propionic acid (I) shows anti-inflammatory, analgesic and antipiretic properties.
The anti-inflammatory activity has been determined for compound (I) by comparison with Alclofenac, as per the Carrageenan test comprising the oral administration of the test compound suspended in oil to albino female rats with 100 g average weight one hour before the subcutaneous perfusion of 0.1 ml of 1% carrageenan in distilled water into the hind-right paw of the rat.
In Table l,the activity is expressed as the decrease rate of the induced edema volume and is hereinafter computed for a series of dosage.
_ Compound I Alclofenac _ Dose (mg/kg) Activity (%) Dose (mg/kg) Activity (%) .:
2.5 25.7 2.5 16.88 35.45 5 23.38 45.79 10 28.52 .
The antipiretic activity has been determined for compound (I) by comparison with Alclofenac. The method used consisted in inducing fever in albino male rats (100-150 g weight) by subcutaneous injection of brewer's yeast (20%
suspension in sodium chloride 0.9 % dissolution) at a dose of 10 ml/kg.
~
: - . . . .
.: , : . :. : . :~
108~7631 In Table 2, the activity is expressed as the decrease rate of the induced temperature and is hereinafter computed for a series of dosage.
Compound I Alclofenac Dose (mg/kg) Activity (%)Dose (mg/kg) Activity (%)
3.12 22 3.12 21 6.25 76 6.25 17 12.5 84 12.5 34 The toxicity of compound (I) in mice by the oral route showed LD50 values of 3.45 g/kg and LDo values of 2.13 g/kg, the LD50 for Alclofenac being 1.10 g/kg.
The higher activity of the compound of the present invention compared to Alclofenac as well as its lower toxicity makes it drug of choice for clinical treatment of diseases involving inflammatory, algesic or pyretic processes. The compound can be administered, mixed with suitable excipients, in the form of tablets, capsules, syrup, solution, etc. by the oral route as well as by rectal route at a daily dose ranging between 30 and 2,400 mg.
The invention will now be illustrated with reference to the following non restrictive examples.
Example 1 : ethyl /3-chloro-4-methoxypheny~/ acetate (III, 1 2 5) A mixture of 60.80 g of /3-chloro-4-methoxypheny acetonitrile, 100 ml of ethanol and 37.0 ml of concentrated sulphuric acid is left overnight under reflux. The cold mixture is diluted with water and extracted with ether which is washed with concentrated sodium carbonate solution and water till neutralization, it is thereafter dried and evaporated. The :
.. . ~ : ' crude product weighs 68.2 g. IR spectrum and elemental analysis agree with the proposed structure.
EXAMPLE 2 diethyl /3-chloro-4-methoxypheny~J malonate (IV, Rl = R2 C2 5) In a flask provided with a small column and a distillation device is heated at 100-110C in oil bath, a mixture of 67.2 g of ethyl /3-chloro-4-methoxypheny~J acetate and 225 ml of diethyl carbonate. Then a solution of sodium ethoxide in ethanol prepared from 8.09 g of sodium and 145 ml of absolute ethanol is added over 30 minutes.
Once all ethanol is distilled and the excess of diethyl carbonate begins to flow, heating is stopped. The residue is acidified with acetic acid and water, then extracted with ether which is washed with saturated sodium carbonate solution and water till neutralization. Once the ether is cvaporated, the residue weighs 70.2g' by distillation, 50.5 g (160-170C/l mmHg) are obtained, which on solidification in the course of time show a melting point of 45-8C. IR spectrum and elemental analysis agree with the proposed structure.
EXAMPLE 3 : diethyl /3-chloro-4-methoxypheny~J methylmalonate (V, Rl = R2 = C2 5) 58.7 g of diethyl /3-chloro-4-methoxypheny~J malonate in 45 ml of absolute ethanol are added to a solution, under stirring, of sodium ethoxide in ethanol prepared with 4.50 g of sodium and 175 ml of absolute ethanol. After adding 32 ml of methyliodide, the solution is left under reflux for 3 hours, then distilled in alcohol, diluted with water and extracted with ether which is washed and dried; once the ether is evapo-rated, the oily residue weighs 50.3 g and it is used for the ~;
following step with no more purification.
EXAMPLE 4 : a-/3-chloro-4-methoxypheny~J propionic acid (VI) The above oil (50.0 g) is left under reflux for 2 ~' :.
., , ~ - .
: :: :. : . . . ~ .
hours with a mixture of 175 ml of 5N sodium hydroxide solution and 250 ml of ethanol, then it is evaporated, extracted with ether (which is rejected) and the waters are acidified, under cooling, with concentrated hydrochloric acid, the insoluble residue is taken in ether, washed with water and dried. Once the solvent is evaporated, the residue weighs 41 g and corresponds to /3-chloro-4-methoxypheny~J methylmalonic acid.
The acid obtained is heated in an oil bath at 210-220C till complete decarboxylation (about 20 minutes). The residue is distilled and 30.2 g (140-150C/0.1 mmHg) are obtain-ed. IR and NMR spectra and elemental analysis agree with the proposed structure.
EXAMPLE 5 : a-/3-chloro-4-hydroxypheny~J propionic acid (VII) (obtained according to Scheme A) 28.4 g of ~-/3-chloro-4-methoxypheny ~ propionic acid in 175 ml of 48% aqueous bromhydric acid are left under reflux for 15 hours. The excess of bromhydric acid is evaporated under vacuum, then taken in benzene, washed and dried. Once the benzene is evaporated, the residue weighs 26.3 g and it is used for the following step with no more purification.
EXAMPLE 6 : a-/3-chloro-4-hydroxypheny~J propionic acid (VII) (obtained according to Scheme B) 35 g of a-/3-chloro-4-methoxypheny~/ propionitrile in 150 ml of 4a% aqueous bromhydric acid are left under reflux for 15 hours. The bromhydric acid is evaporated under vacuum, then the residue in benzene is washed and dried. Once the benzene is evaporated, the residue weighs 32 g and it is used for the next step with no more purification.
EXAMPLE 7 : ~-/3-chloro-4-hydroxypheny~J propionic acid (VII) -(obtained according to Scheme C) 25.0 g of ethyl ~-/3-chloro-4-methoxyphenyl/ propionate in 160 ml of 48% aqueous bromhydric acid are left under reflux .
~08763~
for 15 hours, then the bromhydric acid is evaporated under vacuum, the residue is taken in benzene, washed and dried.
Once the benzene is evaporated, the separated product weighs 23.2 g and it is used for the following step with no more purification.
EXAMPLE 8 : methyl ~-/3-chloro-4-hydroxypheny~ propionate ; ( ' 1 3) A mixture of 26.2 g of a-/3-chloro-4-hydroxypheny~/
propionic acid, 140 ml of methanol and 1.0 g of p-toluensulphonic acid is left under reflux for 15 hours. The methanol is eva-porated under vacuum, diluted with water and extracted with ether; the organic solution is washed with sodium bicarbonate solution and water. The crude product weighs 25.7 g. IR
spectrum agrees with the proposed structure.
EXAMPLE 9 : methyl ~-/3-chloro-4-cyclopropylmethyloxypheny~J
propionate (IX, Rl = CH3) 16.04 g of ~-bromomethylcyclopropane are added with`
vigorous stirring to a mixture of 25.5 g of a-/3-chloro-4-hydroxypheny~/ propionate in 80 ml of anhydrous acetone and 16.4 g of anhydrous potassium carbonate. It is left under reflux, diluted (once cooled) with water and extracted with ether, then washed with sodium carbonate solution, water and dried. The residue weighs 28.3 g. By distillation, 24.6 g (128-132C/0.20 mmHg) are obtained. nD = 1.5305. IR and NMR
spectra agree with the proposed structure.
EXAMPLE 10 : ~-/3-chloro-4-cyclopropylmethyloxy/ propionic acid (I) 13.6 g of methyl ~-/3-chloro-4-cyclopropylmethylox~
propionate are added to a dissolution of 5.66 g of potassium 3Q hydroxide in 12 ml of water and 50 ml of methanol and it is left under reflux for 2 hours. The methanol is evaporated, diluted ~ -with water and acidified with 3N hydrochloric acid, then the ; ~;
_ g _ : , , . , ~ -, . . .
-~087631 insoluble residue is extracted with ether (twice with 150 ml), washed and dried, once the ether is evaporated, the residue weighs 11.08 g. By recrystallization in hexane, 8.0 g of product are obtained. Melting point 44C. IR, RMN spectra and elemental analysis agree with the proposed structure.
EXAMPLE 11~ 3-chloro-4-methoxyphenyl/ propionitrile (X) A solution of 54.45 g of ~-/3-chloro-4-methoxypheny~/
acetonitrile and 70.95 g of methyl iodide in 250 ml of methylene chloride is added with stirring to a mixture of 66.6 g of tetrabutylammonium acid sulphate and 26.4 g of sodium hydroxide in 250 ml of water. Then, it is kept under stirring for 15 minutes, the organic layer is decanted, the methylene chloride is evaporated and the tetrabutylammonium iodide precipitates from the residue by adding ether, then filtered and the ethereal solution is evaporated thus obtaining 59 g of crude product which are distilled to give 48 g (102C/0.1 mmHg).
By cooling the distilled liquid, 10.1 g of unaltered starting product crystallize.
EXAMPLE 12: ethyl ~-/3-chloro-4-methoxypheny~/ propionate (XI, Rl 2 5) 34.53 g of ethyl /3-chloro-4-methoxypheny~/ acetate in 40 ml of anhydrous ether are added for 30 minutes to a mixture of 0.15 moles of sodamide in liquid ammonia prepared from 3.45 g of sodium and 400 ml of ammonia. After 10 minutes, 21.29 of methyl iodide in 20 ml of anhydrous ether are added for 15 minutes, then the mixture is stirred for 1 hour at -40C. The ammonia is allowed to evaporate, it is diluted with ether, then water is carefully added and the organic extract is washed with a solution of sodium bisulfite and water. By distillation under vacuum from the residue, 26.18 g are obtained (105D-8C/0.25 mmHg).
.
The higher activity of the compound of the present invention compared to Alclofenac as well as its lower toxicity makes it drug of choice for clinical treatment of diseases involving inflammatory, algesic or pyretic processes. The compound can be administered, mixed with suitable excipients, in the form of tablets, capsules, syrup, solution, etc. by the oral route as well as by rectal route at a daily dose ranging between 30 and 2,400 mg.
The invention will now be illustrated with reference to the following non restrictive examples.
Example 1 : ethyl /3-chloro-4-methoxypheny~/ acetate (III, 1 2 5) A mixture of 60.80 g of /3-chloro-4-methoxypheny acetonitrile, 100 ml of ethanol and 37.0 ml of concentrated sulphuric acid is left overnight under reflux. The cold mixture is diluted with water and extracted with ether which is washed with concentrated sodium carbonate solution and water till neutralization, it is thereafter dried and evaporated. The :
.. . ~ : ' crude product weighs 68.2 g. IR spectrum and elemental analysis agree with the proposed structure.
EXAMPLE 2 diethyl /3-chloro-4-methoxypheny~J malonate (IV, Rl = R2 C2 5) In a flask provided with a small column and a distillation device is heated at 100-110C in oil bath, a mixture of 67.2 g of ethyl /3-chloro-4-methoxypheny~J acetate and 225 ml of diethyl carbonate. Then a solution of sodium ethoxide in ethanol prepared from 8.09 g of sodium and 145 ml of absolute ethanol is added over 30 minutes.
Once all ethanol is distilled and the excess of diethyl carbonate begins to flow, heating is stopped. The residue is acidified with acetic acid and water, then extracted with ether which is washed with saturated sodium carbonate solution and water till neutralization. Once the ether is cvaporated, the residue weighs 70.2g' by distillation, 50.5 g (160-170C/l mmHg) are obtained, which on solidification in the course of time show a melting point of 45-8C. IR spectrum and elemental analysis agree with the proposed structure.
EXAMPLE 3 : diethyl /3-chloro-4-methoxypheny~J methylmalonate (V, Rl = R2 = C2 5) 58.7 g of diethyl /3-chloro-4-methoxypheny~J malonate in 45 ml of absolute ethanol are added to a solution, under stirring, of sodium ethoxide in ethanol prepared with 4.50 g of sodium and 175 ml of absolute ethanol. After adding 32 ml of methyliodide, the solution is left under reflux for 3 hours, then distilled in alcohol, diluted with water and extracted with ether which is washed and dried; once the ether is evapo-rated, the oily residue weighs 50.3 g and it is used for the ~;
following step with no more purification.
EXAMPLE 4 : a-/3-chloro-4-methoxypheny~J propionic acid (VI) The above oil (50.0 g) is left under reflux for 2 ~' :.
., , ~ - .
: :: :. : . . . ~ .
hours with a mixture of 175 ml of 5N sodium hydroxide solution and 250 ml of ethanol, then it is evaporated, extracted with ether (which is rejected) and the waters are acidified, under cooling, with concentrated hydrochloric acid, the insoluble residue is taken in ether, washed with water and dried. Once the solvent is evaporated, the residue weighs 41 g and corresponds to /3-chloro-4-methoxypheny~J methylmalonic acid.
The acid obtained is heated in an oil bath at 210-220C till complete decarboxylation (about 20 minutes). The residue is distilled and 30.2 g (140-150C/0.1 mmHg) are obtain-ed. IR and NMR spectra and elemental analysis agree with the proposed structure.
EXAMPLE 5 : a-/3-chloro-4-hydroxypheny~J propionic acid (VII) (obtained according to Scheme A) 28.4 g of ~-/3-chloro-4-methoxypheny ~ propionic acid in 175 ml of 48% aqueous bromhydric acid are left under reflux for 15 hours. The excess of bromhydric acid is evaporated under vacuum, then taken in benzene, washed and dried. Once the benzene is evaporated, the residue weighs 26.3 g and it is used for the following step with no more purification.
EXAMPLE 6 : a-/3-chloro-4-hydroxypheny~J propionic acid (VII) (obtained according to Scheme B) 35 g of a-/3-chloro-4-methoxypheny~/ propionitrile in 150 ml of 4a% aqueous bromhydric acid are left under reflux for 15 hours. The bromhydric acid is evaporated under vacuum, then the residue in benzene is washed and dried. Once the benzene is evaporated, the residue weighs 32 g and it is used for the next step with no more purification.
EXAMPLE 7 : ~-/3-chloro-4-hydroxypheny~J propionic acid (VII) -(obtained according to Scheme C) 25.0 g of ethyl ~-/3-chloro-4-methoxyphenyl/ propionate in 160 ml of 48% aqueous bromhydric acid are left under reflux .
~08763~
for 15 hours, then the bromhydric acid is evaporated under vacuum, the residue is taken in benzene, washed and dried.
Once the benzene is evaporated, the separated product weighs 23.2 g and it is used for the following step with no more purification.
EXAMPLE 8 : methyl ~-/3-chloro-4-hydroxypheny~ propionate ; ( ' 1 3) A mixture of 26.2 g of a-/3-chloro-4-hydroxypheny~/
propionic acid, 140 ml of methanol and 1.0 g of p-toluensulphonic acid is left under reflux for 15 hours. The methanol is eva-porated under vacuum, diluted with water and extracted with ether; the organic solution is washed with sodium bicarbonate solution and water. The crude product weighs 25.7 g. IR
spectrum agrees with the proposed structure.
EXAMPLE 9 : methyl ~-/3-chloro-4-cyclopropylmethyloxypheny~J
propionate (IX, Rl = CH3) 16.04 g of ~-bromomethylcyclopropane are added with`
vigorous stirring to a mixture of 25.5 g of a-/3-chloro-4-hydroxypheny~/ propionate in 80 ml of anhydrous acetone and 16.4 g of anhydrous potassium carbonate. It is left under reflux, diluted (once cooled) with water and extracted with ether, then washed with sodium carbonate solution, water and dried. The residue weighs 28.3 g. By distillation, 24.6 g (128-132C/0.20 mmHg) are obtained. nD = 1.5305. IR and NMR
spectra agree with the proposed structure.
EXAMPLE 10 : ~-/3-chloro-4-cyclopropylmethyloxy/ propionic acid (I) 13.6 g of methyl ~-/3-chloro-4-cyclopropylmethylox~
propionate are added to a dissolution of 5.66 g of potassium 3Q hydroxide in 12 ml of water and 50 ml of methanol and it is left under reflux for 2 hours. The methanol is evaporated, diluted ~ -with water and acidified with 3N hydrochloric acid, then the ; ~;
_ g _ : , , . , ~ -, . . .
-~087631 insoluble residue is extracted with ether (twice with 150 ml), washed and dried, once the ether is evaporated, the residue weighs 11.08 g. By recrystallization in hexane, 8.0 g of product are obtained. Melting point 44C. IR, RMN spectra and elemental analysis agree with the proposed structure.
EXAMPLE 11~ 3-chloro-4-methoxyphenyl/ propionitrile (X) A solution of 54.45 g of ~-/3-chloro-4-methoxypheny~/
acetonitrile and 70.95 g of methyl iodide in 250 ml of methylene chloride is added with stirring to a mixture of 66.6 g of tetrabutylammonium acid sulphate and 26.4 g of sodium hydroxide in 250 ml of water. Then, it is kept under stirring for 15 minutes, the organic layer is decanted, the methylene chloride is evaporated and the tetrabutylammonium iodide precipitates from the residue by adding ether, then filtered and the ethereal solution is evaporated thus obtaining 59 g of crude product which are distilled to give 48 g (102C/0.1 mmHg).
By cooling the distilled liquid, 10.1 g of unaltered starting product crystallize.
EXAMPLE 12: ethyl ~-/3-chloro-4-methoxypheny~/ propionate (XI, Rl 2 5) 34.53 g of ethyl /3-chloro-4-methoxypheny~/ acetate in 40 ml of anhydrous ether are added for 30 minutes to a mixture of 0.15 moles of sodamide in liquid ammonia prepared from 3.45 g of sodium and 400 ml of ammonia. After 10 minutes, 21.29 of methyl iodide in 20 ml of anhydrous ether are added for 15 minutes, then the mixture is stirred for 1 hour at -40C. The ammonia is allowed to evaporate, it is diluted with ether, then water is carefully added and the organic extract is washed with a solution of sodium bisulfite and water. By distillation under vacuum from the residue, 26.18 g are obtained (105D-8C/0.25 mmHg).
.
Claims (15)
1. A process for the preparation of a compound of the formula:
(I) and its pharmaceutically acceptable addition salts, which comprises subjecting a corresponding alkyl ester of the formula:
(IX) wherein R1 is a lower alkyl radical, to a saponification reaction carried out in the presence of an alkaline or earth-alkaline hydro-xide in a lower alkanol, and subsequent acidification with a mineral acid.
(I) and its pharmaceutically acceptable addition salts, which comprises subjecting a corresponding alkyl ester of the formula:
(IX) wherein R1 is a lower alkyl radical, to a saponification reaction carried out in the presence of an alkaline or earth-alkaline hydro-xide in a lower alkanol, and subsequent acidification with a mineral acid.
2. A process according to claim 1, wherein the com-pound of the formula (IX) is obtained by reacting a compound of the formyla (VIII) wherein R1 has the aforesaid meaning with an .alpha.-halomethylcyclo-propane of the formula CH2-X where X is chlorine, bromine or iodine in a basic medium and in a low molecular-weight ketone.
3. A process according to claim 2, wherein the com-pound of the formula (VIII) is obtained by esterification of a compound of the formula:
(VII) with an alcohol of the formula R1-OH where R1 has the aforesaid meaning, in the presence of an aryl-sulphonic acid of the formula Ar-SO3H where Ar is a phenyl radical optionally containing one or more lower alkyl radicals.
(VII) with an alcohol of the formula R1-OH where R1 has the aforesaid meaning, in the presence of an aryl-sulphonic acid of the formula Ar-SO3H where Ar is a phenyl radical optionally containing one or more lower alkyl radicals.
4. A process according to claim 3, wherein the compound of the formula (VII) is obtained by acid hydrolysis of a compound of the formula:
(VI) in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid.
(VI) in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid.
5. A process according to claim 4, wherein the compound of the formula (VI) is obtained by basic hydrolysis of a compound of the formula:
(V) wherein R1 and R2 are the same or different and each represents lower alkyl radical, and subsequent decarboxylation of the inter-mediate [3-chloro-4-methoxyphenyl]methylmalonic acid formed.
(V) wherein R1 and R2 are the same or different and each represents lower alkyl radical, and subsequent decarboxylation of the inter-mediate [3-chloro-4-methoxyphenyl]methylmalonic acid formed.
6. A process according to claim 5, wherein the basic hydrolysis of the compound of the formula ( V) is effected by treatment with an alkaline or earth-alkaline hydroxide in a lower alkanol, followed by acidification with a mineral acid.
7. A process according to claim 5,wherein the compound of the formula (V) is obtained by methylation of a compound of the formula:
(IV) wherein R1 and R2 have the aforesaid meaning, with a compound of formula YCH3 where Y is bromine or iodine, in the presence of an alkaline alkoxide in a lower alkanol.
(IV) wherein R1 and R2 have the aforesaid meaning, with a compound of formula YCH3 where Y is bromine or iodine, in the presence of an alkaline alkoxide in a lower alkanol.
8. A process according to claim 7, wherein the compound of the formula (IV) is obtained by treating a compound of the formula:
(III) where R1 has the aofresaid meaning, with a carbonic acid derivative of the formula (R2O)2CO where R2 has the aforesaid meaning, in a basic medium.
(III) where R1 has the aofresaid meaning, with a carbonic acid derivative of the formula (R2O)2CO where R2 has the aforesaid meaning, in a basic medium.
9. A process according to claim 8, wherein the compound of the formula (III) is obtained by reacting a compound of the formula:
(II) with an alkanol of the formula R1-OH where R1 has the aforesaid meaning, in a strong acid.
(II) with an alkanol of the formula R1-OH where R1 has the aforesaid meaning, in a strong acid.
10. A process according to claim 3, wherein the com-pound of the formula (VII) is obtained by acid hydrolisis of a compound of the formula:
(X) in the presence of either an hydracid of formula XH where X is chloride, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid.
(X) in the presence of either an hydracid of formula XH where X is chloride, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid.
11. A process according to claim 10, wherein the com-pound of the formula (X) is obtained by methylation of a compound of the formula:
(II) with a compound of the formula YCH3 where Y is bromine or iodine, in the presence of an alkaline or earth-alkaline hydroxide and an ammonium salt.
(II) with a compound of the formula YCH3 where Y is bromine or iodine, in the presence of an alkaline or earth-alkaline hydroxide and an ammonium salt.
12. A process according to claim 3, wherein the com-pound of the formula (VII) is obtained by acid hydrolysis of a compound of the formula:
(XI) wherein R1 has the aforesaid meaning,in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid.
(XI) wherein R1 has the aforesaid meaning,in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid.
13. A process according to claim 12, wherein the com-pound of the formula (XI) is obtained by methylation of a compound of the formula:
(III) wherein R1 has the aforesaid meaning, with a compound of the for-mula YCH3 where Y is bromine or iodine, in the presence of sodamide in liquid ammonia.
(III) wherein R1 has the aforesaid meaning, with a compound of the for-mula YCH3 where Y is bromine or iodine, in the presence of sodamide in liquid ammonia.
14. A process according to claim 1, which comprises:
a) reacting a compound of the formula:
( I I ) with an alkanol of the formula R1-OH where R1 is a lower alkyl radical, in a strong acid to obtain a compound of the formula:
(III) treating the compound of the formula (III) with a carbonic acid derivative of the formula (R2O)2CO where R2 is a lower alkyl radical, in a basic medium to obtain a compound of the formula:
(IV) methylating the compound of the formula (IV) with a compound of formula YCH3 where Y is bromine or iodine, in the presence of an alkaline alkoxide in a lower alkanol, to obtain a compound of the formula:
(V) wherein R1 and R2 have the aforesaid meanings, subjecting the com-pound of the formula (V) to a basic hydrolysis and decarboxylating the intermediate ?3-chloro-4-methoxypheny?methylmalonic acid formed, to obtain a compound of the formula:
( VI ) and subjecting the compound of the formula (VI) to an acid hydro-lysis, in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid, to obtain a compound of the formula:
(VII) or b) methylating a compound of the formula:
(II) with a compound of the formula YCH3 where Y is bromine or iodine, in the presence of an alkaline or earth-alkaline hydroxide and an ammonium salt, to obtain a compound of the formula:
(X) and subjecting the compound of the formula (X) to an acid hydro-lysis, in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid, to obtain a compound of the formula:
(VII) or c) reacting a compound of the formula:
(II) with an alkanol of the formula R1-OH where R1 is a lower alkyl radical, in a strong acid to obtain a compound of the formula:
(III) methylating the compound of formula (III) with a compound of the formula YCH3 where Y is bromine or iodine, in the presence of soda-mine in liquid ammonia, to obtain a compound of the formula:
(XI) and subjecting the compound of the formula (XI) to an acid hydro-lysis, in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid, to obtain a compound of the formula:
(VII) and d) esterifying the compound of the formula (VII) obtain-ed with an alcohol of the formula R1-OH where R1 is a lower alkyl radical, in the presence of an aryl-sulphonic acid of the formula Ar-SO3H where Ar is a phenyl radical optionally containing one or more lower alkyl radicals, to obtain a compound of the formula:
(VIII) reacting the compound of the formula (VII) with an .alpha.-halomethyl-cyclopropane of the formula where X is chlorine, bromine or iodine, in a basic medium and in alow molecular-weight ketone, to obtain a compound of the formula:
(IX) and subjecting the compound of the formula (IX) to a saponifica-tion carried out in the presence of an alkaline or earth-alkaline in a lower alkanol, and subsequent acidification with a mineral acid.
a) reacting a compound of the formula:
( I I ) with an alkanol of the formula R1-OH where R1 is a lower alkyl radical, in a strong acid to obtain a compound of the formula:
(III) treating the compound of the formula (III) with a carbonic acid derivative of the formula (R2O)2CO where R2 is a lower alkyl radical, in a basic medium to obtain a compound of the formula:
(IV) methylating the compound of the formula (IV) with a compound of formula YCH3 where Y is bromine or iodine, in the presence of an alkaline alkoxide in a lower alkanol, to obtain a compound of the formula:
(V) wherein R1 and R2 have the aforesaid meanings, subjecting the com-pound of the formula (V) to a basic hydrolysis and decarboxylating the intermediate ?3-chloro-4-methoxypheny?methylmalonic acid formed, to obtain a compound of the formula:
( VI ) and subjecting the compound of the formula (VI) to an acid hydro-lysis, in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid, to obtain a compound of the formula:
(VII) or b) methylating a compound of the formula:
(II) with a compound of the formula YCH3 where Y is bromine or iodine, in the presence of an alkaline or earth-alkaline hydroxide and an ammonium salt, to obtain a compound of the formula:
(X) and subjecting the compound of the formula (X) to an acid hydro-lysis, in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid, to obtain a compound of the formula:
(VII) or c) reacting a compound of the formula:
(II) with an alkanol of the formula R1-OH where R1 is a lower alkyl radical, in a strong acid to obtain a compound of the formula:
(III) methylating the compound of formula (III) with a compound of the formula YCH3 where Y is bromine or iodine, in the presence of soda-mine in liquid ammonia, to obtain a compound of the formula:
(XI) and subjecting the compound of the formula (XI) to an acid hydro-lysis, in the presence of either an hydracid of formula XH where X is chlorine, bromine or iodine, or a mixture of sulphuric acid with bromhydric acid, to obtain a compound of the formula:
(VII) and d) esterifying the compound of the formula (VII) obtain-ed with an alcohol of the formula R1-OH where R1 is a lower alkyl radical, in the presence of an aryl-sulphonic acid of the formula Ar-SO3H where Ar is a phenyl radical optionally containing one or more lower alkyl radicals, to obtain a compound of the formula:
(VIII) reacting the compound of the formula (VII) with an .alpha.-halomethyl-cyclopropane of the formula where X is chlorine, bromine or iodine, in a basic medium and in alow molecular-weight ketone, to obtain a compound of the formula:
(IX) and subjecting the compound of the formula (IX) to a saponifica-tion carried out in the presence of an alkaline or earth-alkaline in a lower alkanol, and subsequent acidification with a mineral acid.
15. A compound of the formula:
(I) and its pharmaceutically acceptable addition salts, whenever obtain-ed by a process according to claims 1 or 14 or their obvious chemical equivalents.
(I) and its pharmaceutically acceptable addition salts, whenever obtain-ed by a process according to claims 1 or 14 or their obvious chemical equivalents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA295,499A CA1087631A (en) | 1978-01-24 | 1978-01-24 | 2-phenylpropionic acid derivative and process for its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA295,499A CA1087631A (en) | 1978-01-24 | 1978-01-24 | 2-phenylpropionic acid derivative and process for its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1087631A true CA1087631A (en) | 1980-10-14 |
Family
ID=4110611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA295,499A Expired CA1087631A (en) | 1978-01-24 | 1978-01-24 | 2-phenylpropionic acid derivative and process for its preparation |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA1087631A (en) |
-
1978
- 1978-01-24 CA CA295,499A patent/CA1087631A/en not_active Expired
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1076134A (en) | Process for preparing phenylacetic acid ester derivatives | |
CH647520A5 (en) | NORTROPANE DERIVATIVES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
JPS62234078A (en) | Benzopyranyl and benzothiopyranyl benzene compound, its production and cosmetics and drug for human and animal | |
JP2603620B2 (en) | Eicosatriinamide-5,8,11 compound, method for producing the same, and pharmaceutical composition | |
JPS6332058B2 (en) | ||
US4472430A (en) | Alpha-alkyl polyolefinic carboxylic acids and derivatives thereof useful in the treatment of psoriasis | |
EP0335164A2 (en) | Ester derivatives of neopentanol, process for their preparation and their use as medicines | |
DE2755759A1 (en) | 4- (4-ACYL-3-HYDROXY-8-METHYLTRIDECYL) - BENZOIC ACIDS | |
CA1324134C (en) | Process for preparing (rs)-2-(2,3-dihydro-5-hydroxy-4,6, 7-trimethylbenzofuranyl) acetic acids and 2-(2,3-dihydro-5-acyloxy-4,6,7-trimethylbenzofuranyl) acetic acids and esters thereof, useful as mucoregulator and antihyschaemic drugs | |
EP0074170B1 (en) | Chroman compounds, process for producing them and pharmaceutical compositions containing them | |
DD299423A5 (en) | PROCESS FOR THE PREPARATION OF NAPHTHALENE DERIVATIVES | |
CA1087631A (en) | 2-phenylpropionic acid derivative and process for its preparation | |
KR100224330B1 (en) | N- 4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl)carbonyl)amino acids | |
JPS6399057A (en) | Glycine derivative | |
US4181736A (en) | Phenylacetic acid derivatives and therapeutic composition containing same | |
JPS6360015B2 (en) | ||
US3741988A (en) | Novel benzoylphenylacetic acid esters | |
US3682964A (en) | Spiro benzocyclane acetic acid compounds | |
DE2903094B2 (en) | Naphryl-1-acetic acid derivatives, processes for their preparation and compositions containing them | |
FR2478640A1 (en) | Antiinflammatory phenyl thieno pyridazinone(s) - prepd. by reaction of hydrazine hydrate and benzoyl thiophene carboxylic acid | |
US4031133A (en) | Phenylacetic acids | |
EP0094738B1 (en) | Pharmaceutical benzodioxane compounds and process for their manufacture | |
CA1060903A (en) | Pharmaceutically useful indanylpropionic acid derivatives | |
US3075997A (en) | 3, 5-dihydroxy-3-fluoro-methylpentanoic acid and the delta lactone thereof | |
NO121502B (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |